by Jeff Berwick, The Dollar Vigilante:
You know what’s almost as rewarding as being right about Bitcoin? The satisfaction of saying “I told you so” to all the powerful naysayers who scoffed at crypto years before it became today’s most profitable trend.
And that’s what the new documentary “Bitcoin: Beyond the Bubble” does so well, capturing the establishment freakout we in the crypto world have painstakingly endured for so many years.
It was only a few years ago that I was sitting on the set of Fox Business’ Varney & Co TV program, where a flabbergasted and skeptical Stuart Varney sneered at the notion of “taking my real dollars and…then you give me virtual money in return!”
by Richard Malone, Sprott Money:
In an apparent about-face, Wall Street firms are now warming up to Bitcoin. After months of scrutinyand denouncement from prominent figures in finance, such as Jamie Dimon and Warren Buffet, Bitcoin seems to have achieved a level of relevance with some institutional players.
Yesterday, The New York Times published a report that the New York Stock Exchange’s parent company, the Intercontinental Exchange (ICE), is planning a Bitcoin exchange of its own. The platform would enable big investors to buy, hold, and sell the digital currency with swap contracts. If the plans were to come to fruition, the initiative could represent a massive shift in Wall Street’s perception of Bitcoin, as this will be the first direct trading operation launched by a traditional financial market.
With the US set to blacklist Iran from global dollar-based transactions, here’s an idea for Tehran: use Bitcoin to make, and accept, payments from its trading partners. And, there’s even a bank ready to serve Iran when it comes knocking: according to Reuters, German Radoslav Albrecht has founded an online bank that allows clients to transfer loans anywhere in the world using Bitcoin.
That’s right: bitcoin’s money-laundering, capital-controls evading capabilities – the reason why we said it’s going much, much higher back in September 2015 when it was just above $200 – are finally going mainstream. And not only that, but in one move it is disintermediating the multi-trillion industry behind private money creation known as “banking.”
It’s therefore hardly a surprise that the company’s motto is “see no bank, hear no bank, speak no bank.”
by Jeff Berwick, The Dollar Vigilante:
Corporatist retail giant Amazon.com has received approval from the United States Patent and Trademark Office for a technology allowing police to track Bitcoin transactions.
As reported by CNBC, the patent–filed by Amazon Technologies–will “correlate different data streams and sell the combined feed as a subscription to people who want to track that data.”
Bitcoin transactions are specifically used as examples twice in the filing. In the first instance, the patent mentions “a data stream that publishes or includes global bitcoin transactions (or any cryptocurrency transaction)” for use by electronic or internet retailers.
by William Suberg, Coin Telegraph:
The owner of the New York Stock Exchange (NYSE) is mulling letting customers buy and hold Bitcoin, The New York Times reported late Monday, May 7. The move would be the second Wall Street giant in a week to reportedly open up to crypto.
As the New York Times reports, citing “emails and documents” as well as four anonymous sources, NYSE owner Intercontinental Exchange (ICE) is planning to offer traders contracts that eventually result in customers owning the cryptocurrency.
by Simon Black, Sovereign Man:
Every year around this time I attend a small, private event to break bread with some of the most invigorating people I know.
There’s only about 100 people in the room– but they’re all at the top of their game… business and intellectual leaders from a variety of industries.
And we gather each year to build relationships with one another and hear about some cutting edge ideas that are usually 2-3 years from hitting the mainstream.
This past weekend’s event, for example, showcased some revolutionary medical advances, including an approach that targets specific proteins to treat afflictions that are caused by, or exacerbated by inflammation– including cancer, arthritis, etc.